SURAKSHA
Suraksha Diagnostic Limited
Suraksha Diagnostic Limited (SURAKSHA) financial statements and selected valuation metrics through 30 June 2026.
Healthcare›Healthcare›Healthcare Services›Healthcare Service Provider
surakshanet.com(opens the company website in a new tab)Key metrics
Price as of 2026-10-16
Full years shown; sign in free for the trailing twelve months. Learn about these metrics →
Price & valuation
Share price and valuation multiples (P/E, P/B and more) over time.
Loading price history…
Compare with peers
Loading peers…
What you need to know
Suraksha runs a network of diagnostic centres in West Bengal and nearby eastern states, selling pathology and radiology tests, genomic tests and doctor consultations to patients, referring doctors and corporate and public-sector clients.
Company snapshot
7thBy market cap
Ranked among 10 companies in Healthcare Service Provider.
What we see
- ✓Debt-to-equity of 0.01x — the company is largely funded by its own money, not borrowed funds.
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 67 Cr | 60 Cr | 65 Cr | 73 Cr | 79 Cr | 78 Cr | 81 Cr | 88 Cr |
| Operating expenses (approx.) | 44 Cr | 41 Cr | 46 Cr | 49 Cr | 55 Cr | 55 Cr | 57 Cr | 57 Cr |
| EBITDA | 23 Cr | 18 Cr | 19 Cr | 24 Cr | 24 Cr | 23 Cr | 24 Cr | 30 Cr |
| OPM % | 34.7% | 30.7% | 29.5% | 32.7% | 30.6% | 29.8% | 29.9% | 34.7% |
| Other income | 1 Cr | 0.60 Cr | 0.82 Cr | 0.91 Cr | 0.85 Cr | 0.62 Cr | 0.79 Cr | 1 Cr |
| Interest | 2 Cr | 2 Cr | 2 Cr | 3 Cr | 3 Cr | 3 Cr | 4 Cr | 4 Cr |
| Depreciation | 9 Cr | 9 Cr | 9 Cr | 9 Cr | 10 Cr | 11 Cr | 11 Cr | 11 Cr |
| Profit before tax | 14 Cr | 8 Cr | 9 Cr | 12 Cr | 12 Cr | 10 Cr | 10 Cr | 17 Cr |
| Tax % | 25.5% | 25.6% | 22.2% | 26.4% | 26.7% | 28.0% | 38.3% | 22.3% |
| Net profit | 10 Cr | 6 Cr | 7 Cr | 9 Cr | 9 Cr | 7 Cr | 6 Cr | 13 Cr |
| EPS (₹) | ₹1.94 | ₹1.18 | ₹1.42 | ₹1.80 | ₹1.73 | ₹1.44 | ₹1.21 | ₹2.50 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
| Sales | 223 Cr | 190 Cr | 219 Cr | 252 Cr | 310 Cr | Sign in free for the trailing twelve months |
| Operating expenses (approx.) | 161 Cr | 146 Cr | 149 Cr | 171 Cr | 215 Cr | Sign in free for the trailing twelve months |
| EBITDA | 63 Cr | 44 Cr | 70 Cr | 81 Cr | 95 Cr | Sign in free for the trailing twelve months |
| OPM % | 28.1% | 23.1% | 32.0% | 32.2% | 30.7% | Sign in free for the trailing twelve months |
| Other income | 3 Cr | 4 Cr | 4 Cr | 4 Cr | 3 Cr | Sign in free for the trailing twelve months |
| Interest | 9 Cr | 9 Cr | 9 Cr | 8 Cr | 13 Cr | Sign in free for the trailing twelve months |
| Depreciation | 28 Cr | 32 Cr | 33 Cr | 35 Cr | 41 Cr | Sign in free for the trailing twelve months |
| Profit before tax | 28 Cr | 7 Cr | 31 Cr | 41 Cr | 45 Cr | Sign in free for the trailing twelve months |
| Tax % | 25.7% | 10.1% | 26.5% | 25.2% | 29.5% | Sign in free for the trailing twelve months |
| Net profit | 21 Cr | 6 Cr | 23 Cr | 31 Cr | 31 Cr | Sign in free for the trailing twelve months |
| EPS (₹) | ₹3.91 | ₹1.22 | ₹4.43 | ₹5.97 | ₹6.18 | Sign in free for the trailing twelve months |
| Dividend payout % | — | — | — | 0.0% | 0.0% | Sign in free for the trailing twelve months |
The latest four quarters added up, next to each full year
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity capital | 7 Cr | 7 Cr | 7 Cr | 10 Cr | 10 Cr |
| Reserves | 139 Cr | 149 Cr | 173 Cr | 201 Cr | 234 Cr |
| Borrowings | 19 Cr | 14 Cr | 9 Cr | 6 Cr | 2 Cr |
| Other liabilities | 111 Cr | 112 Cr | 112 Cr | 117 Cr | 203 Cr |
| Total liabilities | 276 Cr | 281 Cr | 300 Cr | 334 Cr | 448 Cr |
| Fixed assets (net) | 118 Cr | 113 Cr | 135 Cr | 147 Cr | 194 Cr |
| CWIP | 1 Cr | 2 Cr | 1 Cr | 10 Cr | 35 Cr |
| Investments | — | — | — | 1 Cr | 0 Cr |
| Inventories | 6 Cr | 6 Cr | 7 Cr | 8 Cr | 8 Cr |
| Trade receivables | 7 Cr | 5 Cr | 9 Cr | 14 Cr | 23 Cr |
| Cash & bank | 3 Cr | 2 Cr | 3 Cr | 2 Cr | 3 Cr |
| Other assets | 141 Cr | 153 Cr | 146 Cr | 151 Cr | 185 Cr |
| Total assets | 276 Cr | 281 Cr | 300 Cr | 334 Cr | 448 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash from operating activity | 58 Cr | 44 Cr | 60 Cr | 63 Cr | 82 Cr |
| Cash from investing | -43 Cr | -21 Cr | -35 Cr | -40 Cr | -52 Cr |
| Cash from financing | -14 Cr | -24 Cr | -25 Cr | -24 Cr | -29 Cr |
| Net cash flow | 0.26 Cr | -1 Cr | 0.36 Cr | -0.27 Cr | 0.97 Cr |
| Free cash flow (OCF − Capex) | 39 Cr | 32 Cr | 18 Cr | 21 Cr | 14 Cr |
Ratios
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROCE % | 22.4% | 9.3% | 21.4% | 23.0% | 23.3% |
| ROE % | 14.3% | 4.2% | 13.2% | 15.1% | 13.2% |
| Debtor days | 11 | 9 | 15 | 20 | 27 |
| Inventory days | 38 | 82 | 89 | 99 | 81 |
| Days payable | 83 | 186 | 193 | 168 | 208 |
| Cash conversion cycle | -34 | -96 | -89 | -49 | -100 |
| OCF / EBITDA % | 92.3% | 100.4% | 86.3% | 78.0% | 85.8% |
| OCF / EBITDA % (3 years) | — | — | 91.9% | 86.0% | 83.4% |
| Debt / equity | 0.13 | 0.09 | 0.05 | 0.03 | 0.0071 |
| Current ratio | 1.64 | 1.77 | 1.84 | 1.10 | 1.05 |
| Net debt / EBITDA | 0.25 | 0.27 | 0.09 | 0.04 | -0.02 |